SV Health Investors

What SV Health Investors does

SV Health Investors is a privately-held, transatlantic healthcare investment manager founded circa 1995, headquartered in London (71 Kingsway) with a US office in Boston (28 State Street). The firm operates across three core strategies — Therapeutics (precision-medicine biotech), Healthcare Growth (growth equity and liquidity for healthcare services and technology businesses), and Medtech (medical devices and healthcare technology) — and separately manages the Dementia Discovery Fund (DDF), the world's largest family of specialized venture capital funds investing exclusively in dementia therapeutics. The group consists of three legal entities: SV Health Managers LLP (FCA-authorised, England OC 308829), SV Health Investors LLC (Massachusetts), and SV Health Investors UK Limited.

SV's "platform" comprises 50+ investment professionals and a bench of venture partners and operating executives across Boston and London, supported by proprietary company-creation capabilities, academic partnerships (Cancer Research UK, Cardiff University), and anchor relationships with seven leading pharmaceutical companies in DDF. The firm has raised over $4.0B in historical commitments across multiple SV Biotech, Healthcare Growth, Medtech, and DDF funds (SV Life Sciences Funds 3–6, SV Fund IV Continuation Fund, SV7 Growth Fund, SV7+ Growth Fund, SV7 Impact Medicine Fund, SV Biotech Crossover Opportunities Fund, SV8 Biotech Fund, DDF-1 £250M and DDF-2 $269M). Track record includes 75 IPOs and M&A exits and 24 novel therapeutic approvals.

Revenue is generated through management fees on committed/invested capital across multiple funds plus carried interest negotiated bilaterally with LPs; specific fee terms are not publicly disclosed. Portfolio companies are sourced through direct institutional LP relationships, academic and pharma partnerships, a venture partner and operating executive network, and an entrepreneur-facing contact channel, with LP reporting delivered through Juniper Square and Intralinks investor portals.

Name

SV Health Investors

Legal name

SV Health Investors, LLC / SV Health Managers LLP / SV Health Investors UK Limited (collectively, the "SV Health Investors group")

Website

https://svhealthinvestors.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

51–100 employees

Short description

SV Health Investors is a privately-held, transatlantic healthcare investment manager running Therapeutics, Healthcare Growth, Medtech, and Dementia Discovery Fund strategies with $4B+ in historical commitments, 75 IPO/M&A exits, and a 50-person team across Boston and London.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital and Private Equity

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Healthcare venture capital
• Biotech investment funds
• Private equity healthcare
• Medical device investing
• Dementia therapeutics funding

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Fund Management Fees and Carried Interest: SV Health Investors generates revenue primarily through recurring management fees on committed/invested capital across its multiple SV Biotech, Healthcare Growth, Medtech, and Dementia Discovery funds, supplemented by carried interest (carried interest terms governed by individual fund Limited Partnership Agreements). The firm has raised over $4.0B in historical commitments across SV's global PE/VC platform and over $600M for the DDF strategy alone (DDF-1 £250M + DDF-2 $269M). Revenue is managed and reported under SV Health Managers LLP in the UK (FCA-regulated, registered in England OC 308829) and SV Health Investors LLC in the US.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

SV Health Investors is a transatlantic private healthcare investment manager that deploys capital through three strategies — Therapeutics, Healthcare Growth, and Medtech — via dedicated fund vehicles such as the SV8 Biotech Fund, SV7+ Growth Fund, and Dementia Discovery Fund. The firm invests in innovative biotech, healthcare services, and medical device companies, supports portfolio companies with operating expertise and proactive company creation, and earns revenue through management fees and carried interest on capital commitments from institutional limited partners.

Product overview

SV Health Investors is a private investment firm focused exclusively on healthcare and life sciences, not a traditional technology product company. Its offering is a platform-plus-modules architecture composed of three investment strategies — Therapeutics, Healthcare Growth, and Medtech — each backed by a series of dedicated funds. The Therapeutics strategy is supported by funds such as the SV8 Biotech Fund (the newest fund, with $100M backing from the British Business Bank), the SV Biotech Crossover Opportunities Fund, the SV7 Impact Medicine Fund, the SV Life Sciences Funds 3-4, 5-6, SV Fund IV Continuation Fund, and the Dementia Discovery Fund-1 (DDF-1) and Dementia Discovery Fund-2 (DDF-2), with DDF-2 reaching $269M at final close in 2025. The Healthcare Growth strategy is supported by the SV7 Growth Fund and SV7+ Growth Fund. The Medtech strategy is supported by the Medtech Convergence Fund. Together, these fund families comprise SV's healthcare investment platform, with $4.0B in historical commitments, 75 IPOs/M&As, and a 30-year track record across US and UK.

Differentiator

Problem solved

Functional benefit

Brands

• SV8 Biotech Fund: Core SV biotech fund for precision medicine investments from early stage to late stage growth.
• SV7+ Growth Fund
• SV7 Growth Fund
• SV7 Impact Medicine Fund
• SV Biotech Crossover Opportunities Fund
• Dementia Discovery Fund (DDF)

Products and services

• SV Therapeutics Strategy SV Health Investors' Therapeutics strategy invests across the full biotech investment spectrum from early stage to late stage growth, focusing on precision medicine biotech. The team includes investment professionals, operating executives, and venture partners in the UK and US who back companies developing high-impact precision medicine drugs for poorly treated diseases.
• SV Healthcare Growth Strategy SV Health Investors' Healthcare Growth strategy provides growth capital and liquidity for industry leaders transforming healthcare, backing healthcare services and healthcare technology businesses that have achieved scale and need capital to accelerate growth, strategic acquisitions, and market expansion.
• SV Medtech Strategy SV Health Investors' Medtech strategy invests in compelling teams and technologies with the power to change medicine, focusing on medical device and healthcare technology companies, supported by the Medtech Convergence Fund.
• SV8 Biotech Fund SV Health Investors' biotech-focused investment fund for precision medicine therapeutics innovation from early-stage to late-stage growth, with UK life sciences focus. Investor access is provided through the Intralinks portal.
• SV7+ Growth Fund SV Health Investors growth investment fund for healthcare services and healthcare technology growth equity opportunities. Investor access is provided through the Juniper Square portal.
• SV7 Growth Fund SV Health Investors growth investment fund for healthcare services and healthcare technology. Investor access is provided through the Juniper Square portal.
• SV7 Impact Medicine Fund SV Health Investors fund focused on impact-oriented medicine investments. Investor access is provided through the Intralinks portal.
• SV Biotech Crossover Opportunities Fund SV Health Investors fund focused on crossover biotech investment opportunities, typically late-stage pre-IPO rounds. Investor access is provided through the Intralinks portal.
• Dementia Discovery Fund-1 (DDF-1) The first dementia-focused venture capital fund family investing exclusively in companies developing or enabling novel therapeutics for dementia; backed by seven leading pharmaceutical companies (Biogen, Eli Lilly, GSK, Johnson & Johnson, Otsuka/Astex, Pfizer, Takeda) plus AARP, Bill Gates, British Patient Capital, and others. Managed by SV Health Investors.
• Dementia Discovery Fund-2 (DDF-2) The second vintage of the world's largest family of specialized venture capital funds investing exclusively in companies developing novel therapeutics for dementia. Managed by SV Health Investors, the fund capitalizes on global investment opportunities to deliver measurable impact and financial returns. Investor access is provided through the Intralinks portal.
• SV Life Sciences Funds 3-4 SV Life Sciences Funds 3-4 are legacy healthcare/biotech venture fund vintages operated by SV Health Investors. Investor access is provided through the AltaReturn portal (svlsa.altareturn.com).
• SV Life Sciences Funds 5-6 SV Life Sciences Funds 5-6 are healthcare/biotech venture fund vintages operated by SV Health Investors. Investor access is provided through the Juniper Square portal.
• SV Fund IV Continuation Fund SV Fund IV Continuation Fund is a continuation vehicle operated by SV Health Investors. Investor access is provided through the Juniper Square portal.
• Medtech Convergence Fund The Medtech Convergence Fund is SV Health Investors' fund vehicle supporting its Medtech strategy, investing in medical device and healthcare technology companies.

Quantifiable outcome

• 24 novel therapeutics approved as a result of SV investment (as of January 2024)
• +5 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

13 partnerships are on record, tiered major, flagship and minor.

• EpiVax, Inc. (acquisition)majorOEM/ Whitelabel/ Licensing Partner · 2 April 2026SV Health Investors announced the acquisition of EpiVax, a bioanalytical CRO based in Providence, RI, specializing in immunogenicity risk assessments for pharmaceutical and biotech clients (April 2026). The acquisition aims to accelerate EpiVax's development in immunogenicity risk assessment, expand its scientific capabilities into advanced computational tools, cell-based assay applications, and broader analytical services. Deal value not disclosed.
• Boehringer Ingelheim (Sitryx licensing)flagshipOEM/ Whitelabel/ Licensing Partner · 26 February 2026Boehringer Ingelheim licensed a novel, preclinical oral small molecule program from SV portfolio company Sitryx Therapeutics for autoimmune and inflammatory disease indications (announced February 26, 2026). Deal terms include upfront and milestone payments to Sitryx totaling more than $500 million, plus tiered royalties. Boehringer assumes full responsibility for further research, clinical development and commercialization. SV's seed-funded Sitryx is one of the firm's flagship immunology bets.
• Innovative Consulting Group (ICG) / Pivot Point Consulting / Health Enterprise Partners / Petra Capital PartnersmajorStrategic or Co-development Partner · 17 February 2026SV Health Investors' portfolio company Innovative Consulting Group (ICG) acquired Pivot Point Consulting from Highspring, with the deal backed by a consortium of investors including SV Health Investors, Health Enterprise Partners, and Petra Capital Partners. The combined entity operates under the Pivot Point Consulting brand, offering expanded managed services (Best in KLAS), strategic advisory, and talent solutions to providers, payers, life sciences, and healthcare technology organizations. SV initially partnered with HIT executives Dave Dyell and Marc Hirshfield to lead the recapitalization of ICG in November 2023.
• Packaging Compliance Labs (PCL) — Quest Engineering Solutions acquisitionminorStrategic or Co-development Partner · 14 May 2025SV Health Investors-backed Packaging Compliance Labs (PCL) acquired Quest Engineering Solutions, a Billerica, MA-based ISO 17025-accredited testing laboratory, to expand geographic reach and testing capabilities in medical device and life sciences markets. The acquisition expands PCL's staff and services and is supported by SV as a portfolio company of the healthcare growth strategy.
• Ferrer (Prilenia co-development & commercialization)majorStrategic or Co-development Partner · 28 April 2025SV portfolio company Prilenia entered into a Collaboration and License Agreement with Ferrer (April 2025) for the commercialization and co-development of pridopidine in Europe and other select markets. Prilenia retains full commercialization and development rights in North America, Japan and Asia Pacific. Together they are advancing pridopidine for Huntington's Disease (Phase 3) and ALS (Phase 3 PREVAiLS trial). Nature Medicine published Phase 3 PROOF-HD data in September 2025 supporting a planned confirmatory study.
• Centauri Health Solutions — MedAllies acquisitionminorStrategic or Co-development Partner · 24 April 2025SV Health Investors portfolio company Centauri Health Solutions acquired MedAllies, a healthcare interoperability provider based in New York, to enhance clinical data exchange and connectivity services. The acquisition supports Centauri's effort to improve access to care and financial support through expanded data solutions and networks.
• Robling Medical (controlling interest acquisition)majorOEM/ Whitelabel/ Licensing Partner · 20 June 2023SV Health Investors announced the acquisition of a controlling interest in Robling Medical, a healthcare-focused contract manufacturer, on June 20, 2023. The investment supports Robling's organic growth and strategic acquisitions, emphasizing its role as a trusted partner in medical device manufacturing.
• Cancer Research UKflagshipStrategic or Co-development PartnerStrategic partnership with Cancer Research UK, the world's largest independent funder of cancer research, to accelerate the development of cancer medicines. SV has priority access to Cancer Research UK's world-leading research, providing the opportunity to rapidly develop and scale innovative research into new drugs. The partnership is positioned as a continuation and strengthening of SV's previous collaboration with CRUK.
• Cardiff University (Medicines Discovery Institute)flagshipStrategic or Co-development PartnerDraig Therapeutics was founded in 2024 through a partnership between Cardiff University's Medicines Discovery Institute (MDI) and SV Health Investors. The company was created on the back of research from Cardiff and emerged from stealth in June 2025 with $140 million in total investment. Lead compound DT-101 entered Phase 2 trials in 2025 for Major Depressive Disorder. The partnership reflects SV's strategy of building companies from world-class academic science.
• Merck (MSD) — EyeBio acquisitionflagshipOEM/ Whitelabel/ Licensing PartnerSV Health Investors-created EyeBio was acquired by Merck (MSD) for $1.3 billion upfront (up to $3 billion total deal value), recognized as Exit of the Year at The EUVC Awards 2025. The EyeBio deal represents one of SV's largest exits; EyeBio is developing Restoret for retinal diseases. David Guyer (SV Venture Partner) cofounded Eyetech Pharmaceuticals and led EyeBio to the sale.
• Eli Lilly and Company (Alchemab licensing & collaboration)majorOEM/ Whitelabel/ Licensing PartnerSV portfolio company Alchemab entered an exclusive global licensing agreement with Eli Lilly and Company in May 2025 for ATLX-1282 (with Lilly leading further development and commercialization; Alchemab conducting the first-in-human study). Alchemab also announced a separate research collaboration with Lilly in January 2025 for the discovery, research, development and commercialization of up to five novel therapeutic candidates for neurodegenerative disease (initially ALS). Eli Lilly is also an existing investor in Alchemab and Trex Bio.
• Merck & Co. (MSD) — Mestag licensingmajorOEM/ Whitelabel/ Licensing PartnerSV portfolio company Mestag Therapeutics, founded by SV Health Investors, entered a License and Research Collaboration with MSD (Merck & Co., Inc., Rahway, NJ) in October 2024 to identify novel targets for inflammatory diseases using Mestag's specialist fibroblast-immune RAFT Platform. Mestag has also previously licensed a novel target to Johnson & Johnson under a 2021 target discovery, option and license agreement with Janssen Biotech, Inc.
• Life Biosciences (David Guyer board appointment)minorStrategic or Co-development PartnerLife Biosciences appointed David Guyer, M.D. (SV Health Investors Venture Partner) to its Board of Directors in November 2025 to support the development of cellular rejuvenation therapies, including lead program ER-100 advancing into human trials in early 2026. Dr. Guyer co-founded Eyetech Pharmaceuticals and led EyeBio to its sale to Merck.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Atlas Venture: Boston-based early-stage biotech venture firm with a comparable focus on company creation, transatlantic operations, and seed-to-Series A biotech investing — closely overlapping SV's Therapeutics strategy and company-creation playbook.
• Sofinnova Partners: Paris/London-based European biotech VC with a similar stage focus (seed to late clinical) and overlapping investment themes in oncology and rare disease — directly comparable to SV's European biotech activities and a co-investor in Sitryx.
• Forbion: European healthcare-focused VC manager with multiple funds across biotech stages; a direct co-investor in Mestag Therapeutics and a similar profile in precision medicine and immunology to SV's Therapeutics strategy.
• Versant Ventures: Healthcare-specialist VC with parallel biotech, medtech, and healthcare growth strategies across the US/Europe/Canada; led Dualitas alongside SV participation — directly comparable multi-strategy healthcare platform.
• OrbiMed: Healthcare-dedicated investment firm with $20B+ AUM across private equity, venture, and royalty strategies; one of the largest direct competitors to SV in biotech and growth-stage healthcare investing.
• RA Capital Management: Boston-based healthcare-focused investment manager with crossover and venture strategies; co-led Artios Pharma's $115M Series D with SV, illustrating direct overlap in biotech company building and crossover investing.
• Abingworth: UK-based healthcare VC manager with biotech and growth strategies; co-led AdvanCell's $112M Series C alongside SV — directly comparable transatlantic healthcare investor with similar stage focus.
• ARCH Venture Partners: US-based biotech-focused venture firm with a long track record of company creation; comparable early-stage biotech thesis, large fund vintages, and high-impact therapeutic focus to SV's Therapeutics strategy.

Broad incumbents

• New Enterprise Associates (NEA): Large diversified PE/VC with a substantial healthcare practice spanning biotech, medtech, and services; overlaps SV's Healthcare Growth and Medtech strategies but with broader sector exposure outside healthcare.
• Blackstone Life Sciences: Large incumbent life sciences investment platform within Blackstone; comparable in scale and late-stage biotech/medtech deal-making, but operates as part of a broader alternatives portfolio rather than a healthcare specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInsvhealthinvestors.com/ (no direct SV Health Investors LinkedIn URL is provided in the source data; LinkedIn references in the input relate to portfolio companies such as Prilenia and Cerevance, not SV Health Investors itself)
• Xx.com/SVLifeSciences

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles31 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments338 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SV Health Investors